Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$22.93 USD
+0.41 (1.82%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $22.92 -0.01 (-0.04%) 5:32 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Company Summary
Cambridge, MA-based Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.
In Vivo Programs: Intellia has multiple in vivo programs. The company is evaluating its leading in vivo genome-editing candidates — NTLA-2001 for the treatment of transthyretin (ATTR) ...
Company Summary
Cambridge, MA-based Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.
In Vivo Programs: Intellia has multiple in vivo programs. The company is evaluating its leading in vivo genome-editing candidates — NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE). Intellia is planning to file an investigational new drug (IND) application seeking approval to begin clinical studies on NTLA-3001 for alpha-1 antitrypsin deficiency (AATD)-associated lung disease shortly.
Ex Vivo Programs: Intellia is developing multiple preclinical programs that utilize its allogeneic platform for the treatment of immuno-oncology and autoimmune diseases. These programs are being developed as wholly-owned and also in collaboration with partners.
NTLA-2001 is part of a co-development and co-promotion agreement with Regeneron Pharmaceuticals. While Intellia is the lead party for NTLA-2001, Regeneron shares 25% of the development costs and commercial profits. Intellia and Regeneron are also working on developing therapies for hemophilia A and hemophilia B, with Regeneron being the lead party.
Intellia is currently identifying collaboration opportunities to advance the development of NTLA-6001 for CD30+ lymphomas.
With no marketed products in its portfolio, Intellia Therapeutics only generates collaboration revenues. In 2023, the company generated $36.3 million of collaboration revenues compared with $52.1 million in 2022.
General Information
Intellia Therapeutics, Inc
40 Erie Street Suite 130
Cambridge, MA 02139
Phone: 857-285-6200
Fax: NA
Web: http://www.intelliatx.com
Email: lina.li@intelliatx.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/14/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -1.38 |
Current Year EPS Consensus Estimate | -5.44 |
Estimated Long-Term EPS Growth Rate | 1.10 |
Exp Earnings Date | 11/14/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 22.52 |
52 Week High | 34.94 |
52 Week Low | 19.21 |
Beta | 1.77 |
20 Day Moving Average | 1,188,410.25 |
Target Price Consensus | 69.14 |
4 Week | -4.62 |
12 Week | -1.70 |
YTD | -26.14 |
4 Week | -4.57 |
12 Week | -4.16 |
YTD | -37.29 |
Shares Outstanding (millions) | 101.58 |
Market Capitalization (millions) | 2,287.56 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 6.43% |
vs. Previous Quarter | -23.58% |
vs. Previous Year | -48.82% |
vs. Previous Quarter | -75.96% |
Price/Book | 2.24 |
Price/Cash Flow | NA |
Price / Sales | 44.19 |
6/30/24 | -47.12 |
3/31/24 | -45.35 |
12/31/23 | -43.91 |
6/30/24 | -38.62 |
3/31/24 | -37.40 |
12/31/23 | -36.42 |
6/30/24 | 7.21 |
3/31/24 | 9.03 |
12/31/23 | 8.67 |
6/30/24 | 7.21 |
3/31/24 | 9.03 |
12/31/23 | 8.67 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | -1,106.87 |
3/31/24 | -922.94 |
12/31/23 | -1,326.51 |
6/30/24 | 10.06 |
3/31/24 | 10.74 |
12/31/23 | 11.73 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |